NCT02544750 - An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions

Tuberous Sclerosis ComplexSeizures

Interventions

DRUG

GWP42003-P

Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston